ライフサイエンスコーパス: posttreatment

1 during the training sessions and at pre- and posttreatment.

2 incentive delay task (MIDT) pretreatment and posttreatment.

3 Patients were followed until 1 year posttreatment.

4 g administration (baseline), 2 h, and 7 days posttreatment.

5 mine and underwent repeated rs-fcMRI at 24 h posttreatment.

6 ups with no significant differences pre- and posttreatment.

7 eek 4, end of treatment, and 6 and 12 months posttreatment.

8 the same amount of initial DNA damage by 3 h posttreatment.

9 P < .001) were significantly more prevalent posttreatment.

10 1 year, with no further increases at 2 years posttreatment.

11 low pretreatment and increased 1 and 2 years posttreatment.

12 ion against FMDV challenge at 6, 24, or 48 h posttreatment.

13 ere counted on H&E-stained sections 24 hours posttreatment.

14 s 6 h after treatment and for at least 120 h posttreatment.

15 fferent responses for each tumor at mid- and posttreatment.

16 sponse with undetectable HCV RNA at 9 months posttreatment.

17 erienced vision loss; however, most improved posttreatment.

18 hereas AHR was abrogated between 3 and 10 wk posttreatment.

19 h a sustained virologic response at 12 weeks posttreatment.

20 4, 48, and 72 hours and 5, 7, 9, and 14 days posttreatment.

21 er treatment, and this remained elevated 3 h posttreatment.

22 ; 12 (31%) reported residual visual symptoms posttreatment.

23 not predictive of clinical failure assessed posttreatment.

24 t randomization, biweekly, midtreatment, and posttreatment.

25 n the CD group during anticipatory phases at posttreatment.

26 4 and follow-up visits occurred for 9 months posttreatment.

27 recorded at baseline, 3 hours, and 24 hours posttreatment.

28 Baseline and posttreatment 1.5T and 7T MR imaging was done, and histo

29 All patients underwent systematic posttreatment (18)F-FDG PET/CT and were followed with at

30 For this, the performance of posttreatment (18)F-FDG PET/CT, the impact on patient ca

31 ith escitalopram; remission was defined as a posttreatment 24-item Hamilton Depression Rating Scale <

32 WAZ score were examined from pretreatment to posttreatment (6 months) and change in HAZ score was ass

33 ation is a viable method for determining the posttreatment (90)Y distribution in the liver.

34 estimates of absorbed doses calculated from posttreatment (90)Y TOF PET/CT for tumor and nontumor ti

35 (7 glass spheres, 20 resin spheres) and the posttreatment (90)Y TOF PET/CT results.

36 nt (99m)Tc-MAA SPECT to predict intrahepatic posttreatment (90)Y-microsphere distribution.

37 One patient who died before week 12 posttreatment achieved a response at posttreatment week

38 symptoms significantly improved from pre- to posttreatment across all conditions and were maintained

39 In CD participants, increased posttreatment activity in dopamine-innervated regions su

40 ADC ratio (mean posttreatment ADC/mean pretreatment ADC) was calculated.

41 recurrence among MSM and may be an effective posttreatment adjuvant form of therapy.

42 Active surveillance for posttreatment adverse events was performed daily for 6 d

43 Posttreatment adverse events were similar following DEC

44 Long interval between radiotherapy and posttreatment AMT PET as well as high radiation dose aff

45 ccuracy than those receiving placebo at both posttreatment and 1 month follow up.

46 m severity than those assigned to placebo at posttreatment and at follow-up.

47 DCS group but not the placebo group, at both posttreatment and follow-up (clinician-rated Y-BOCS: t62

48 e Clinician-Administered PTSD Scale score at posttreatment and PTSD diagnosis at 3 months posttreatme

49 efore treatment, 6 underwent a second PET/CT posttreatment, and 1 a third during follow-up.

50 llected at baseline, each treatment session, posttreatment, and 1-month follow-up.

51 , which was maximal at approximately 24 hour posttreatment, and 3-methyl adenine or knock down of Bec

52 Baseline, posttreatment, and 6-month follow-up assessments were ma

53 f social anxiety were acquired pretreatment, posttreatment, and at 3-month follow-up.

54 findings consolidate a disease framework for posttreatment anemia in malaria in which delayed hemolys

55 ARR over 5 years (mean [SD] pretreatment vs posttreatment ARR, 2.4 [1.5] vs 0.3 [1.0]).

56 nhibition of MAPK and PI3K/AKT activation in posttreatment as compared with pretreatment tumor specim

57 and remission rates (34.5% and 24.4%) at the posttreatment assessment; response and remission rates w

58 Posttreatment assessments took place 1 hour, 1 week, and

59 ity were calculated between pretreatment and posttreatment assessments; subsequently, the overall dif

60 ia at week 12 (SVR12) and at week 24 (SVR24) posttreatment, at which time all had a clinical response

61 Our data suggest that pre- and posttreatment Bcl-2/IgH levels from PB have significant

62 A positive posttreatment Bcl-2/IgH status was associated with short

63 Posttreatment biopsies were obtained in 15 patients and

64 healthy control subjects matched by age and posttreatment BMI of study group participants.

65 How baseline and posttreatment body composition affects outcome is unknow

66 tive assessment in paired, pretreatment, and posttreatment bone marrow samples shows that Pre-PCs are

67 direct Sanger sequencing of samples pre- and posttreatment, but not on more sensitive deep sequencing

68 IgE/IgG1 responses, was substantial at 3 wk posttreatment, but progressively increased thereafter, s

69 Minimal residual disease (MRD) was assessed posttreatment by a polymerase chain reaction-based ligas

70 al costs for pretreatment, on-treatment, and posttreatment care were calculated using data from Medic

71 Relative to pretreatment, at posttreatment CD participants demonstrated increased ant

72 Posttreatment cell culture and enzyme-linked immunosorbe

73 symptom score across days 2 to 4 of a 4-day posttreatment challenge (PTC) in the EEU after the grass

74 renchymal enhancement (BPE) (n = 91, 20.9%), posttreatment changes (n = 16, 3.8%), and other findings

75 In this study, posttreatment clinical and immunologic reactions were co

76 elationship between pretreatment binding and posttreatment clinical status was examined.

77 y gene-modified hepatocytes observed 4 weeks posttreatment compared to traditional rAAV gene delivery

78 sma cells into the brain around the tumor in posttreatment compared with pretreatment samples.

79 pite the presence of post-Lyme symptoms, all posttreatment culture results were negative, antiborreli

80 9; P < 0.001), whereas second-phase decline (posttreatment days 4-15) did not differ between the two

81 gh 7 days after treatment) and in follow-up (posttreatment days 8-210), after adjustment for sociodem

82 mRNA expression, pre- and posttreatment, demonstrated significant downregulation o

83 Remission was defined as a posttreatment depression score of less than 10 as well a

84 ip between pretreatment amygdala binding and posttreatment depression score, and were unable to predi

85 depression score, and were unable to predict posttreatment depression severity using both pretreatmen

86 ther brain region, GABA levels at 4 weeks or posttreatment did not differ between patients with FEP a

87 all mean difference between pretreatment and posttreatment distribution of activity concentration for

88 Posttreatment dorsolateral prefrontal cortex activation

89 ictive dosimetry of (99m)Tc-MAA SPECT/CT and posttreatment dosimetry based on (90)Y time-of-flight (T

90 tative (90)Y bremsstrahlung SPECT to improve posttreatment dosimetry.

91 ng on intent-to-treat outcomes, within-group posttreatment effect sizes for CPT and prolonged exposur

92 Posttreatment EMVI status (yEMVI) was reevaluated for bo

93 ate by 6% for headache freedom at the 2-hour posttreatment end point owing to study design.

94 sion:(18)F-FDG PET/CT shows good accuracy in posttreatment evaluation of anal cancer and has a releva

95 Posttreatment evaluation was conducted with contrast mat

96 In the posttreatment evaluation, neurocognitive function was si

97 n the detection of distant metastasis and in posttreatment evaluation.

98 Pre- and posttreatment expression of EGFR and HER3 was compared u

99 While the posttreatment fall in hemoglobin level was greater in se

100 All had pre- and posttreatment FDG PET/CT scans.

101 Intratumoral pre- and posttreatment FDG-standardized uptake values (SUV1, SUV2

102 In RCTs with posttreatment follow-up >/=12 months, antiviral therapy

103 In RCTs with posttreatment follow-up <12 months, antiviral therapy co

104 endpoint was undetectable HCV RNA at 6-month posttreatment follow-up (sustained virological response;

105 DG PET/CT may play a significant role during posttreatment follow-up of anal cancer.

106 Posttreatment follow-up ranged from 35 to 124 months (me

107 s ratio = 0.66, P < .036), during the 2-year posttreatment follow-up, and during the entire 5-year tr

108 se in all patients who completed 12 weeks of posttreatment follow-up.

109 ociated with less cannabis use during 1-year posttreatment follow-up.

110 ine, or PBO); and 24 months of longitudinal, posttreatment follow-up.

111 %) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to

112 ation transfer images were obtained pre- and posttreatment from veterans with (n=39) and without PTSD

113 comparison conditions for target symptoms at posttreatment (g=-0.153, 90% equivalence CI=-0.227 to -0

114 In the posttreatment glioma group, high thalamic SUVs and high

115 vioral therapy for insomnia (CBT-I) improved posttreatment global and most sleep outcomes, often comp

116 nalysis to determine mean slopes of pre- and posttreatment growth curves on a per-tumor basis and wer

117 growth curves was used to determine pre- and posttreatment growth curves on a per-tumor basis.

118 Noninferiority was shown for posttreatment HAM-D and patient-rated depression scores

119 BDI decrease >/=95%), and superior response (posttreatment HAM-D or BDI score of 0) using multilevel

120 -D or >/=9 BDI points), extreme nonresponse (posttreatment HAM-D score >/=21 or BDI score >/=31), sup

121 Secondary outcome measures included mean posttreatment HAM-D score and patient-rated depression s

122 Posttreatment histology was examined by light and transm

123 Although the mean baseline and posttreatment HOMA values were similar in SVR patients (

124 llar arterial anastomosis, were recorded and posttreatment imaging results were reviewed.

125 Uptake on pre- and posttreatment imaging was measured and compared.

126 DW imaging before treatment; 26 completed a posttreatment imaging.

127 posttreatment in 4 individuals, and 4 weeks posttreatment in 1 patient (14 IU/mL).

128 NA (range, 15-57 IU/mL) was measured 2 weeks posttreatment in 4 individuals, and 4 weeks posttreatmen

129 eosinophil granule proteins, were increased posttreatment in both groups.

130 n, iron absorption, and utilization pre- and posttreatment in children with afebrile malaria, hookwor

131 were measured before, and 1 year and 2 years posttreatment in whole blood cultures stimulated with so

132 g loss with HBV DNA <2,000 IU/mL at 6 months posttreatment) in 45%.

133 d evidence of a previously undetected strain posttreatment; in many studies, this is interpreted as r

134 nhanced social functioning was mirrored by a posttreatment increase in their blood OXT concentrations

135 Posttreatment increases in the levels of IgE to schistos

136 No baseline or posttreatment indices correlated with percentage of resi

137 Finally, at early time points posttreatment, infection with IAVs caused higher levels

138 ient in the SLT group (2.0%) had a transient posttreatment IOP spike greater than 5 mm Hg.

139 Bacterial vaginosis (BV) recurrence posttreatment is common.

140 We examined whether isoflurane posttreatment is protective against early brain injury a

141 c infiltration from normal-appearing skin to posttreatment lesional skin to active skin lesions in pa

142 We examined whether pretreatment and posttreatment levels of cognitive restraint, disinhibiti

143 emistry (IHC) was performed on both pre- and posttreatment liver biopsies of 59 PIVENS patients rando

144 ment was assessed by paired pretreatment and posttreatment liver biopsies, magnetic resonance elastog

145 and three ADV-treated (14%) patients during posttreatment long-term follow-up with an overall annual

146 data suggesting possible mechanisms by which posttreatment Lyme disease could occur.

147 nodiagnosis was negative in 16 patients with posttreatment Lyme disease syndrome (PTLDS) and/or high

148 ponse to this protein is not associated with posttreatment Lyme disease syndrome.

149 ns suggest that the entities referred to as "posttreatment Lyme disease" and "chronic Lyme disease" m

150 Serum samples from 37 patients with posttreatment Lyme syndrome, as well as 40 medically hea

151 Primary tumor size was assessed on pre- and posttreatment magnetic resonance images according to 1D

152 ention (NCT00957229), using pretreatment and posttreatment magnetic resonance imaging.

153 nd immature gametocytes but does not prevent posttreatment malaria transmission.

154 The pre- and posttreatment mean VAS scores significantly differed (7.

155 wed greater improvement from pretreatment to posttreatment (mean difference, -3.62; 95% CI, -0.81 to

156 0.956]) and higher for all pretreatment than posttreatment measurements (ICC, 0.761 [95% CI: 0.209, 0

157 ordance correlation coefficient for pre- and posttreatment measurements was 0.83 (95% confidence inte

158 Posttreatment medium entropy of less than 7.356 (median

159 relationship between tumor-absorbed dose and posttreatment metabolic activity was assessed per metast

160 eport at baseline, at weeks 8 and 16, and at posttreatment months 3 and 6.

161 mors were manually delineated on T2-weighted posttreatment MR images and registered to the posttreatm

162 Immediate contrast-enhanced posttreatment MR imaging showed a hypovascular defect in

163 Absence of late enhancement at posttreatment MR imaging was significantly associated wi

164 Posttreatment MRI reassessment indicated a "safe" ymrLRP

165 y [n = 3], and both pretreatment [n = 9] and posttreatment [n = 9]).

166 ll as in cell lines and tissues derived from posttreatment NB tumors.

167 duced changes were sustained over the entire posttreatment observation interval (25-78 min) and consi

168 patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years.

169 e were 33 cases (pretreatment only [n = 12], posttreatment only [n = 3], and both pretreatment [n = 9

170 Median (range) time from earliest posttreatment oral HPV16 DNA detection to recurrence was

171 ated with curative intent, 124 had 1 or more posttreatment oral rinses available and were included in

172 although infrequent, persistent HPV16 DNA in posttreatment oral rinses is associated with poor progno

173 gies for detecting MRD and correlations with posttreatment outcomes.

174 e any changes with trastuzumab up to 12 days posttreatment (P > 0.05).

175 ular metabolism in vivo as early as 48 hours posttreatment (P < 0.05), whereas fluorodeoxyglucose-pos

176 Clinical pre- and posttreatment parameters were assessed, the inflammatory

177 motherapy using pretreatment clinical stage, posttreatment pathologic stage, estrogen receptor (ER) s

178 PrepN-stage and posttreatment pathological N-stage (ypN-stage) were comb

179 PrepN-stage and posttreatment pathological N-stage (ypN-stage) were comb

180 n 7 of the 8 appearance scales compared with posttreatment patients (exception was skin) (P < .001 to

181 Pretreatment and posttreatment patients 18 years and older who were consu

182 From April 2005 to August 2008, 783 pre- and posttreatment PB samples were quantified by quantitative

183 t 24 hours after therapy) and in the delayed posttreatment period (days 2-5 after therapy).

184 rol of both nausea and vomiting in the acute posttreatment period (first 24 hours after therapy) and

185 In the posttreatment period, C. difficile counts similarly pers

186 rall tumor response (OR) of 70% after a 4-wk posttreatment period.

187 ere collected during cooling, rewarming, and posttreatment periods (8 d).

188 Pre- and posttreatment PET comparative scans should ideally be ob

189 Pre- and posttreatment PET scans were acquired in protocols compl

190 Posttreatment PET/CT (Deauville) predicts overall surviv

191 Posttreatment PET/CT (Deauville) showed significantly in

192 The specificity of posttreatment PET/CT (Deauville) was 95.7% versus 76.4%

193 Posttreatment PET/CT showed identical results, compared

194 rall survival; MRD status is the single best posttreatment predictor of long-term outcomes after CIT.

195 Monitoring posttreatment proteolysis may lead to a novel class of i

196 Posttreatment quit status after treatment, defined as a

197 Posttreatment randomization follow-up data collected ove

198 peripheral blood, at a median of 12.8 years posttreatment (range, 9.5-14.7).

199 The annual posttreatment rate of clinical events in hepatitis delta

200 tologic and immunologic changes suggest that posttreatment reactions following DEC and IVM share a co

201 to the occurrence of immune-mediated severe posttreatment reactions following ivermectin distributio

202 bset-specific analysis demonstrated that the posttreatment rebound was driven by the CD4(+)CD25(+)Fox

203 phology, incorporation of side branches, and posttreatment recanalization, and should be considered a

204 ) are thought to drive tumor progression and posttreatment recurrence in multiple solid tumors.

205 ls of functional specific CD8 T cells at 8 d posttreatment reflected by both in vivo killing and IFN-

206 ocetaxel) or tumor irradiation abolished the posttreatment regrowth of primary prostate tumors in mic

207 ment failure was due to nonresponse (n = 2), posttreatment relapse (n = 9), reinfection (n = 1), and

208 metastatic progression, drug resistance, and posttreatment relapses, but how cancer cells adapt and e

209 The primary outcome measure was posttreatment remission rate (HAM-D score </=7).

210 The average posttreatment remission rate was 22.7%.

211 ion scores but could not be demonstrated for posttreatment remission rates or any of the follow-up me

212 eatment, at week 3, and after treatment) and posttreatment remission status based on cut points.

213 d 5-HT1A binding could improve prediction of posttreatment remission status.

214 latively stable for at least 6 and 12 months posttreatment, respectively.

215 Pretherapy planning and posttreatment response assessments rely heavily on gadol

216 It also highlights the importance of posttreatment restaging.

217 7T MR images obtained at 16 hours posttreatment revealed a significant reduction in signal

218 sson and Cox regression to evaluate pre- and posttreatment risk factors for infection, respectively.

219 y help to educate clinicians and patients on posttreatment risk, prevention, and management of lymphe

220 previously undetected variant present in the posttreatment sample in addition to a variant that was d

221 ignificantly differ between pretreatment and posttreatment samples and serum contained predominantly

222 All 11 participants who had MRM detected in posttreatment samples failed azithromycin.

223 Pre- and posttreatment samples were assessed for macrolide resist

224 abolic response rates, indicated by negative posttreatment scans.

225 However, mean posttreatment scores for CPT and prolonged exposure rema

226 1,700 patients provided individual pre- and posttreatment scores on the Hamilton Depression Rating S

227 Pretreatment and posttreatment sera were obtained from 48 women with meta

228 In 7 patients with posttreatment serum available for analysis, we observed

229 erum prostate-specific antigen values in the posttreatment setting, are also presented.

230 ie early therapeutic efficacy, whereas these posttreatment sex differences contribute to clinical tre

231 nce was associated with having the same pre-/posttreatment sexual partner (adjusted HR [AHR] = 1.9; 9

232 recurrence was increased with the same pre-/posttreatment sexual partner and inconsistent condom use

233 Immune monitoring posttreatment showed an increase in effector T cells rec

234 ion of rTMD23 in mice, both pretreatment and posttreatment, significantly increased the survival rate

235 transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with m

236 istologic comparison of the pretreatment and posttreatment skin was performed using serial internal c

237 osttreatment MR images and registered to the posttreatment SPECT images (n = 9) or SPECT/CT images (n

238 A pretreatment and posttreatment study was conducted in 51 participants (me

239 Posttreatment surrogate end points, such as progression

240 most useful test for initial staging and in posttreatment surveillance settings.

241 the ITG with unquantifiable HCV RNA 12 weeks posttreatment (sustained virological response 12 weeks a

242 omarker identifies patients at high risk for posttreatment symptomatic RP.

243 Posttreatment texture parameters are associated with sur

244 At posttreatment, the D-cycloserine group had the lowest co

245 VM) or fall (post-DEC) in the first 24 hours posttreatment, the eosinophil count rose significantly i

246 From pretreatment to posttreatment, the intervention increased daily energy i

247 lymphocyte counts during the first 24 hours posttreatment, the overall pattern of hematologic and im

248 posttreatment and PTSD diagnosis at 3 months posttreatment; the alprazolam group showed a higher rate

249 At the posttreatment time point, SOL improved by 19.03 (95% CI,

250 ical size predictors at the early, mid-, and posttreatment time points, respectively, were 0.14, 0.09

251 h strong emphasis on pretreatment and day-15 posttreatment to allow earlier and more individualized i

252 in cocaine dependence (CD) pretreatment and posttreatment to determine whether these changes relate

253 related to glycogenesis and the detection of posttreatment tumor quiescence.

254 both sorafenib-treated groups, baseline and posttreatment tumor targeting of (111)In-girentuximab we

255 In posttreatment tumor tissue of patients with malignant gl

256 ferentially expressed in pretreatment versus posttreatment tumors.

257 gical activity from the delivered CPT in the posttreatment tumors.

258 ted at follow-up had lower SEA, but not SWA, posttreatment type 2 responsiveness.

259 Recurrent infection after a negative posttreatment UBT and factors associated with successful

260 Of the 281 with positive posttreatment UBT results, 138 completed re-treatment, o

261 ed in 11.5% of participants who had negative posttreatment UBT results.

262 Posttreatment VA did not reach baseline targets, and the

263 Pre- and posttreatment values were compared using Wilcoxon signed

264 ts receiving azathioprine (AZA) therapy, and posttreatment Vdelta2 T cell recovery correlated with ti

265 ease patients as positive at the baseline or posttreatment visit than two-tiered testing (87.5% and 6

266 Posttreatment visual acuity could be predicted based on

267 S (pretreatment volume < 15 cm(3), P < .003; posttreatment volume < 7.5 cm(3), P < .05; percentage ch

268 the study group (respective median pre- and posttreatment volume: 76.1 cm(3) and 58.4 cm(3) for read

269 he control group (respective median pre- and posttreatment volume: 79.9 cm(3) and 83.8 cm(3) for read

270 Pre- and posttreatment volumes (Wilcoxon signed rank test) and ra

271 seline assessment and at 6 and 14 weeks (the posttreatment/wait assessment).

272 At the posttreatment/wait assessment, 73% of the intensive cogn

273 scopic persistence of P. falciparum on day 3 posttreatment was associated with subsequent microscopic

274 7.4] years), improvement in PTSD severity at posttreatment was greater when CPT was administered indi

275 measure was sustained virologic response at posttreatment week 12 (SVR12) in patients with a genotyp

276 ed virologic response (HCV RNA <25 IU/mL) at posttreatment week 12 (SVR12).

277 Sustained virologic response at posttreatment week 12 (SVR12).

278 atients with sustained virologic response at posttreatment week 12 (SVR12).

279 dpoint was sustained virological response at posttreatment week 12 (SVR12).

280 at analysis, sustained virologic response at posttreatment week 12 was achieved in 100% (6/6, 95% con

281 tudy outcome was SVR12 (HCV-RNA <25 IU/mL at posttreatment week 12) in patients naive to treatment.

282 l below the lower limit of quantification at posttreatment week 12).

283 One patient died at posttreatment week 3; this was not considered related to

284 week 12 posttreatment achieved a response at posttreatment week 4.

285 One patient relapsed at posttreatment week 4.

286 At posttreatment Week 48, daclatasvir-resistant variants pe

287 ith HCV RNA >/=1,000 IU/mL at Week 1 through posttreatment Week 48.

288 ent with NS3-R155K at baseline, relapse, and posttreatment Week 48.

289 ons occurred prior to treatment (week 0), at posttreatment (week 24), and at 6 months after treatment

290 ve (13)C-urea breath test (UBT) 6 to 8 weeks posttreatment were offered voluntary re-treatment with 1

291 Parasites surviving ACT on day 2 or day 3 posttreatment were significantly more likely than the ba

292 ns of tumor PET response at midtreatment and posttreatment were similar.

293 Paired sequences (pre- and posttreatment) were analyzed.

294 s to SEA were high but reduced 1 and 2 years posttreatment, whereas type 2 responses were low pretrea

295 In murine peritonitis, both pre- and posttreatment with CO inhalation significantly increased

296 The in vivo effects of treatment and posttreatment with rTMD123 on aortic dilatation were mea

297 Consistently, posttreatment with rTMD123 seven days after AAA inductio

298 Posttreatment with SRT1720 significantly improved renal

299 In the third and fourth posttreatment years, annual carbon sink strength of the

300 to metastatic melanoma within the first few posttreatment years.